What is HC Wainwright’s Estimate for REGENXBIO Q1 Earnings?

REGENXBIO Inc. (NASDAQ:RGNX) – Equities researchers at HC Wainwright reduced their Q1 2026 earnings estimates for REGENXBIO in a research report issued on Monday, March 9th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will post earnings per share of ($1.23) for the quarter, down from their prior estimate of ($1.21). HC Wainwright currently has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO’s Q2 2026 earnings at ($1.23) EPS, Q3 2026 earnings at $0.31 EPS, Q4 2026 earnings at ($1.24) EPS and FY2026 earnings at ($3.38) EPS.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.29). The firm had revenue of $30.34 million for the quarter, compared to the consensus estimate of $45.48 million. REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%.

Other equities analysts also recently issued reports about the company. The Goldman Sachs Group lowered their price objective on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Leerink Partners boosted their price objective on shares of REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Stifel Nicolaus boosted their price objective on REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, December 19th. Wall Street Zen lowered shares of REGENXBIO from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Finally, UBS Group reaffirmed an “overweight” rating and issued a $18.00 price objective on shares of REGENXBIO in a research note on Tuesday, February 10th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $27.50.

REGENXBIO Trading Down 4.6%

Shares of RGNX stock opened at $9.90 on Wednesday. The stock has a market cap of $510.94 million, a P/E ratio of -2.63 and a beta of 1.08. The company has a 50 day simple moving average of $11.31 and a two-hundred day simple moving average of $11.46. REGENXBIO has a 12 month low of $5.03 and a 12 month high of $16.19.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue purchased a new stake in shares of REGENXBIO during the third quarter worth $25,000. Aquatic Capital Management LLC acquired a new stake in shares of REGENXBIO in the third quarter valued at approximately $37,000. Jones Financial Companies Lllp boosted its position in REGENXBIO by 44.4% during the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in REGENXBIO by 754.1% during the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 5,000 shares during the period. Finally, Captrust Financial Advisors acquired a new position in shares of REGENXBIO during the 2nd quarter valued at $85,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

Trending Headlines about REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and a $30 price target and raised its FY2026 EPS forecast (from -$3.63 to -$3.38) and materially boosted Q3 2026 to $0.31, signaling conviction in a mid‑year recovery and providing a bullish valuation anchor.
• Positive Sentiment: RBC Capital reiterated its Buy on RGNX, supporting the view that some sell‑side firms still see meaningful upside from current levels. RBC Capital Reaffirms Their Buy Rating on RegenXBio (RGNX)
• Neutral Sentiment: HC Wainwright trimmed its $32 target to $30 (small change in absolute terms versus current price), a minor technical update rather than a change in stance. Benzinga
• Neutral Sentiment: Sector note — uniQure’s shares jumped after news of an FDA gene‑therapy official’s departure, highlighting how regulatory personnel moves can shift sentiment across gene‑therapy names (may influence perception of RGNX but not company‑specific fundamentals). uniQure shares jump after FDA gene therapy chief’s departure
• Negative Sentiment: HC Wainwright cut near‑term EPS estimates (Q1, Q2 and Q4 2026 were revised lower), which signals tougher near‑term financials and could pressure the stock until visibility improves.
• Negative Sentiment: Multiple law firms have filed or are soliciting clients in securities‑class actions against REGENXBIO (Rosen, Pomerantz, Faruqi, Schall, Levi & Korsinsky, Gross, Bronstein, etc.). The wave of litigation and related notices increases legal and settlement risk and is a key negative driver for investor sentiment. Representative notices: Rosen Law Firm notice Levi & Korsinsky note Pomerantz class action alert

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.